Kornimate/medical-research-clean huggingface dataset:
efficacy of a proactive approach to death thoughts in people with advanced cancer

Conditions: Death; Advanced Cancer

Summary: the aim of this study is to demonstrate the efficacy of a proactive intervention to approach death thoughts among people with advanced cancer compared to usual care (the reactive approach) via a feasible approach with previous indicators of efficacy: go-tad (give the opportunity to talk about death). the benefits of the intervention will be evaluated in terms of: reduction of emotional distress and hopelessness and improvement the doctor-patient relationship, as well as improvement of quality of life for the patient. a phase ii randomized controlled mixed methods clinical trial (rct) will be carried out within 4 palliative care units of tertiary care hospitals in catalonia. participants will be persons with advanced cancer defined according to the criteria of the american society of clinical oncology. participants will be randomly assigned to an intervention group or control group. in the intervention group, the participants will receive a medical visit that will include the 4 open-ended questions comprising the go-tad intervention, while the control group will receive usual care. between 24 and 96 hours later, a researcher from outside the center will assess study outcome measures. to strengthen the study conclusions, a qualitative study will be carried out in which the experiences of the participants in the intervention group and of their professionals who administered the go-tad will be explored in depth.


Eligibility criteria:
the inclusion criteria will be: 1. patients with advanced cancer defined according to asco (american society of clinical oncology) criteria referred for the initial palliative care (pc) consultation. 2. age over 18 years 3. ecog 0-3 (functionality status) 4. outpatients and inpatients 5. patients who can sign the informed consent 6. patients with the ability to maintain a conversation the exclusion criteria will be: 1. patients with acute symptoms that may affect their consciousness. 2. patients with any uncontrolled symptoms that prevent collaboration in the study assessed according to clinical judgment 3. moderate or severe cognitive impairment assessed according to clinical judgment 4. patients included in another incompatible clinical trial
mr-linac guided adaptive radiotherapy for inoperable mediastinal tumor

Conditions: Mediastinal Tumor

Summary: this phase ii study is to determine the efficacy and safety of mr-linac guided radiotherapy in patients with inoperable mediastinal tumors.

this phase ii study is to determine the efficacy and safety of mr-linac guided radiotherapy in patients with inoperable mediastinal tumors. patients will receive radiotherapy on the mr-linac treatment machine. the primary end point is 2-year local-recurrence free survival. the secondary end points are objective response rate, 2-y pfs, 2-y os, safety of treatment, dose coverage of targets and dose to normal organs.

Eligibility criteria:
inclusion criteria: * aged 18-75 years * histologically or cytologically confirmed mediastinal cancer * patients with inoperable mediastinal lesions * eastern cooperative oncology group (ecog) performance status 0-1 * normal function of organs and bone marrow within 14 days: total bilirubin 1.5 times or less the upper limits of normal (uln); ast and alt 1.5 times or less the uln; absolute neutrophil count≥ 500 cells/mm3; creatinine clearance rate(ccr) ≥45 ml/min; platelet count≥50,000 cells/mm3; international normalized ratio(inr) ≤1.5#prothrombin time (pt)≤ 1.5 × uln * informed-consent exclusion criteria: * patients with contraindications for mri * previous radiotherapy or excision for mediastinal tumor * the tumor has completely approached, encircled, or invaded the intravascular space of the great vessels (e.g., the pulmonary artery or the superior vena cava) * a cavity over 2cm in diameter of primary tumor or metastasis bleeding tendency or coagulation disorder * hemoptysis (1/2 teaspoon blood/day) happened within 1 month * the use of full-dose anticoagulation within the past 1 month * severe vascular disease occurred within 6 months * gastrointestinal fistula, perforation or abdominal abscess occurred within 6 months * hypertensive crisis, hypertensive encephalopathy, symptomatic heart failure (new york class ii or above), active cerebrovascular disease or cardiovascular disease occurred within 6 months * uncontrolled hypertension (systolic \> 150mmhg and/or diastolic \> 100mmhg) * major surgery within 28 days or minor surgery or needle biopsy within 48 hours * urine protein 3-4+, or 24h urine protein quantitative \>1g * severe uncontrolled disease * uncontrollable seizure or psychotic patients without self-control ability * women in pregnancy, lactation period * other not suitable conditions determined by the investigators

Keywords: mediastinal tumor mr-linac radiotherapy
genetic mosaicism in hirschsprung's disease

Conditions: Hirschsprung Disease

Summary: hirschsprung's disease is a complex genetic disorder. the etiology of this disease is not completely understood. it is characterized by the absence of ganglia (nerve cells) in de distal colon. this impairs bowel relaxation which can lead to bowel disfunction, toxic megacolon, ileus and enterocolitis. so far, several genes have been identified that play a role in hirschsprung's disease. the precise mechanisms however, remain unclear. this study wants to identify new mutations and hopefully clarify more about the etiology of the disease.


Eligibility criteria:
inclusion criteria: * all children with hirschsprung's disease that will receive a corrective pull through procedure exclusion criteria: * none

Keywords: hereditary diseases colon
a study of aripiprazole in patients with schizophrenia in general psychiatric practices

Conditions: Schizophrenia and Schizoaffective Disorder

Summary: the purpose of this clinical research study is to evaluate the overall effectiveness of 8 week of aripiprazole treatment.


Eligibility criteria:
inclusion criteria: * diagnosis of schizophrenia or schizoaffective disorder being treated as outpatients,no response to past antipsychotic treatment and patients who symptoms are notoptimally controlled defined as cgi- s\<7 exclusion criteria: * pregnant or breastfeeding,patients at risk for committing suicide,diagnosis of mood disorders, delirium, dementia and other cognitive disorders,patients treatment resistant to otherantipyschotic medications and treatment with a long acting psychotic in which the last dose was within 3 months of treatment phase
effect of chemotherapy given either by mouth or by infusion on the quality of life of patients with recurrent ovarian epithelial cancer

Conditions: Ovarian Cancer; Malignant Tumor of Peritoneum; Quality of Life

Summary: rationale: quality-of-life assessment in patients undergoing cancer treatment may help determine the intermediate- and long-term effects of the treatment on these patients. purpose: this clinical trial studies the effects of chemotherapy given by mouth versus chemotherapy given by infusion on quality of life in patients with recurrent ovarian epithelial cancer.

objectives: i. determine the impact of oral versus parenteral chemotherapy on quality of life (qol) in patients with recurrent ovarian epithelial cancer. ii. evaluate the qol over time in this patient population. iii. determine the impact of disease symptoms, treatment side effects, performance status, and ca-125 levels on qol assessment in this patient population. outline: patients receive a baseline quality of life (qol) assessment, an attitudes/preference survey, and a performance status assessment at the time of diagnosis of recurrent disease. patients are nonrandomly assigned to treatment with either iv or oral chemotherapy using drugs based on national comprehensive cancer network guidelines, prior treatment history, and patient preference. qol and performance status assessments are obtained again at 3 and 6 months during treatment. attitudes/preferences are assessed at 6 months. patients are withdrawn from study if treatment regimen is changed from oral to iv, or from iv to oral during this 6 months. projected accrual: a total of 74 patients will be accrued for this study over 12 months.

Eligibility criteria:
disease characteristics: newly diagnosed recurrent ovarian epithelial cancer or recurrent primary peritoneal cancer as evidenced by new clinical or radiologic detected mass or rising serum ca-125 level no progressive disease with ongoing treatment patient characteristics: age: 18 and over performance status: not specified life expectancy: not specified hematopoietic: not specified hepatic: not specified renal: not specified other: fluent in english not pregnant or nursing prior concurrent therapy: biologic therapy: not specified chemotherapy: not specified endocrine therapy: not specified radiotherapy: not specified surgery: not specified

Keywords: recurrent ovarian epithelial cancer peritoneal cavity cancer quality of life
a study to evaluate the efficacy and safety of ocriplasmin in inducing total pvd in subjects with npdr

Conditions: Diabetic Retinopathy; Posterior Vitreous Detachment; Disease Progression

Summary: the purpose of this study is to assess the efficacy and safety of up to 3 intravitreal injections of ocriplasmin (0.0625mg or 0.125mg), in subjects with moderate to very severe non-proliferative diabetic retinopathy (npdr), to induce total posterior vitreous detachment (pvd) in order to reduce the risk of disease progression to proliferative diabetic retinopathy (pdr).


Eligibility criteria:
inclusion criteria: * male or female aged 18 years or older * best-corrected visual acuity (bcva) of 65 letters read or greater (snellen equivalent of 20/50 or better) in the study eye * hba1c ≤ 12%, as assessed by the central laboratory * moderate to very severe npdr as per etdrs severity scale, based on 7 standard field stereo colour fundus photograph * central subfield thickness of ≤ 340µm on spectralis sd-oct or ≤ 320µm on non-spectralis sd oct in the study eye, with or without mild centre-involved diabetic macular oedema * no evidence of total pvd in the study eye * written informed consent obtained from the subject prior to screening procedures exclusion criteria: * history of or current ocular condition in the study eye that may interfere with the assessment of the progression to pdr * presence of epiretinal membrane in the study eye * presence of foveal ischemia in the study eye * presence of pre-retinal or vitreous haemorrhage in the study eye * presence of iris or angle neovascularisation in the study eye * any active ocular / intraocular infection or inflammation in either eye * aphakic study eye * uncontrolled hypertension in the opinion of the investigator * pseudoexfoliation, marfan's syndrome, phacodonesis or any other finding in the investigator's opinion suggesting lens / zonular instability
causes and mechanisms of space hemolysis at high altitudes

Conditions: Anemia; Weightlessness

Summary: anemia is a lack of red blood cells (rbcs) in the circulation. because rbcs carry the oxygen your body needs to function, anemia can affect one's ability to stay awake, alert, and perform physical activities. anemia may happen for several reasons, including increased rbc destruction. anemia often occurs in people who have been in bed for long periods (e.g., if they are very sick) or have decreased mobility (anemia of immobility). interestingly, astronauts who have left earth and traveled in space also return anemic. in fact, 5 decades of nasa data showed that astronauts' anemia was more severe the longer they were in space. in another study, astronauts aboard the international space station were shown to destroy 54% more of their rbcs in space. rbc destruction may be the culprit of space anemia as well as anemia of immobility on earth. the anemia study proposes to measure key aspects of rbc destruction in astronauts in space. these measures will test critical hypotheses on the effects of spaceflight on red blood cells.


Eligibility criteria:
inclusion criteria: * astronauts selected to fly on a space mission. exclusion criteria: * astronauts not selected to fly on a space mission.
triad burden of illness mucositis study

Conditions: Gastrointestinal Mucositis (Defined as Mucositis Involving the Mouth, Esophagus, or Small Intestine)

Summary: observational (non-drug) study to look at the risks and burden of mucositis (sores) involving the mouth, throat and intestines in patients receiving chemotherapy and radiation therapy treatment for various cancer types.

this comprehensive, observational study will prospectively elicit the true incidence (risk) and health and economic burdens of mucosal toxicities associated with anti-cancer drug and radiation therapy. this study will examine the burden of illness of gastrointestinal mucositis (defined as mucositis involving the mouth, esophagus, or small intestine) in the most significant regimens used to treat the most common types of cancers. it is an international investigation in which 1600 patients being treated with specific regimens for cancers of the head and neck, breast, colon, lung (nsclc)and non-hogkin's lymphoma will be prospectively enrolled from centers throughout the us, canada, europe and australia.

Eligibility criteria:
inclusion criteria: * 18 years or older * ability to understand the protocol and willing to provide written informed consent * membership in one of the following sub-cohorts: 1. histologically proven oral cavity or oropharyngeal cancers planned to receive a full cycle of daily single fraction radiation therapy (with or without boost) or imrt +/- chemotherapy. 2. histologically proven laryngeal or hypopharyngeal cancers planned to receive a full cycle of daily single fraction radiation (with or without boost) +/- chemotherapy. 3. histologically proven adenocarcinoma of the colon or rectum planned to receive a minimum of 2 cycles of folfox +/- avastin or erbitux.1 cycle defined as 2 doses of folfox. 4. histologically proven adenocarcinoma of the colon or rectum planned to receive a minimum of 2 cycles of folfiri +/- avastin or erbitux. 1 cycle defined as 2 doses of folfiri. 5. adenocarcinoma of the breast planned to receive a minimum of 2 cycles of tac. 6. histologically proven adenocarcinoma (any primary) planned to receive a minimum of 2 cycles of capecitabine. 7. adenocarcinoma of the breast planned to receive standard or dose-dense doxorubicin and cyclophosphamide (ac) followed by paclitaxel (t) (4 cycles ac followed by 2 cycles t). 8. stage 3a or 3b non-small cell lung cancers planned to receive daily single fraction radiation with or without boost (1 fraction daily for 5-6 weeks) +/- carbo/taxol. 9. b-cell non-hodgkin's lymphoma (nhl) planned to receive at least 2 cycles of chop-14, choep-14, chop-di-14, epoch-14 or chop-21 +/- rituxan
immunogenicity and safety of hpv vaccine gardasil in young women

Conditions: Systemic Lupus Erythematosus

Summary: the purpose of this study is to evaluate the immunogenicity and safety of the hpv vaccine gardasil in young women.

female patients with systemic lupus erythematosus (sle) have been found have higher rates of persistent hpv infections and precancerous lesions compared to the healthy population. the hpv vaccine gardasil has been found to be safe and efficacious in females aged 9 to 26 years. there are no data on the immunogenicity and safety of gardasil in females with sle. immune dysfunction related to sle itself and the immunosuppression secondary to treatment of sle might prevent patients with sle from developing an adequate immune response to the vaccine. also, theoretically, the vaccine might induce a disease exacerbation or production of new autoantibodies. the purpose of this study is to evaluate immunogenicity and safety of gardasil and its effects on autoantibody profile in female sle patients aged 9-26 years

Eligibility criteria:
inclusion criteria: * age: 9 to 26 years of age * gender: female * all patients must fulfill the revised american college of rheumatology classification criteria for sle diagnosis. * current sledai score ≤ 6 * written, witnessed informed consent and/or assent will be obtained from the subject and the subject's parents (if under 18 years of age) or legally acceptable representative prior to enrollment exclusion criteria: * acute exacerbation of disease within past 30 days which required increase in corticosteroid dose, initiation of a new immunosuppressive medication, or hospitalization * current sledai score \> 6 * patients who have received rituximab in the last 6 months, or are currently on cyclophosphamide treatment * history of allergic disease or reactions likely to be exacerbated by any component of the study vaccine * previous administration of any hpv vaccine

Keywords: lupus
regional and seasonal variations in the incidence and causative organisms for post-traumatic wound infections and osteomyelitis after open fractures

Conditions: Infection

Summary: to determine if there is a relationship between people with open fractures and the season and location of where the injury occurred and the infections they develop


Eligibility criteria:
inclusion criteria: open fracture treated surgically between distal radius and distal tibia - exclusion criteria: * gsw unable to follow for one year
extremely low gestatonal age infants' paracetamol study

Conditions: Prematurity; Extreme; Low Birthweight, Extremely (999 Grams or Less)

Summary: in the present trial, early, intravenous paracetamol is compared to placebo in extremely premature or low birth weight infants in order to evaluate the effect on ductal closure.

the purpose of this randomized, placebo-controlled, double-blind, phase 2, one center clinical trial is to study the efficacy and safety of early (\< 96 h) intravenous paracetamol in prophylactic closure of ductus arteriosus in extremely premature (gestational age \<28+0 wk, elga) or low birth weight (\<1000 g, elbw) infants. the infants born extremely preterm or low birth weight are a focus of the study, since a small phase 2 study on paracetamol failed to demonstrate contraction of ductus arteriosus. in the investigator's previous cohort of elga/elbw infants, the numbers of patients who needed any therapies for patent ductus arteriosus (pda) were 29 (23%) in the paracetamol exposed group, and 90 (54%) in the control group. as demonstrated in a phase 2 study, the early paracetamol treatment induced the closure of ductus arteriosus: the mean (sd) ductal closure age was 177 (338) h in the whole paracetamol group. however, in the subgroup of elga infants born before 28 gestation weeks (n=14), the mean (sd) ductal closure ages in the paracetamol and placebo groups were 491 (504) h and 858 (719) h, respectively.

Eligibility criteria:
inclusion criteria: * premature infants born before 28+0 gestation weeks and/or birth weight less than 1000g exclusion criteria: * severe malformation or suspected chromosomal defect or other very severe life-threatening disease (e.g. very severe birth asphyxia or persistent pulmonary hypertension, etc.)

Keywords: acetaminophen ductus arteriosus nirs intravenous
dna tests in detecting disseminated disease in tumor, blood, and bone marrow samples from patients with rhabdomyosarcoma

Conditions: Sarcoma

Summary: rationale: dna analysis of tumor, blood, and bone marrow may help doctors predict if the disease has been disseminated. purpose: this research trial studies dna tests in detecting disseminated disease in tumor, blood, and bone marrow samples from patients with rhabdomyosarcoma.

objectives: * to establish a panel of hypermethylation assays for minimal disseminated disease analysis in rhabdomyosarcoma (rms). * to apply the hypermethylation assays to a series of bone marrow specimens from rms patients. outline: archived tumor, bone marrow, and peripheral blood samples are analyzed for dna hypermethylation by pcr-based assays and microarray assays. results are then compared with each patient's clinical and pathological characteristics, and outcomes. patterns of locus hypermethylation in tumor and paired bone marrow samples are also compared.

Eligibility criteria:
disease characteristics: * diagnosed with rhabdomyosarcoma (rms) * tumor, bone marrow, and peripheral blood samples from the children's oncology group d9803 trial of intermediate-risk rms patient characteristics: * not specified prior concurrent therapy: * not specified

Keywords: alveolar childhood rhabdomyosarcoma embryonal childhood rhabdomyosarcoma embryonal-botryoid childhood rhabdomyosarcoma mixed childhood rhabdomyosarcoma pleomorphic childhood rhabdomyosarcoma previously untreated childhood rhabdomyosarcoma nonmetastatic childhood soft tissue sarcoma
improving the diagnosis of diarrhoea in emergency rooms

Conditions: Diarrhoea

Summary: a point-of-care laboratory (poc) was set at north hospital, marseille, france for the diagnosis in less than two hours of diarrhoea caused by known pathogens, close to the reception of emergency service. in this instance 30% of patients have no etiological diagnosis after the poc diarrhoea tests . this lab has discovered over 200 new species of bacteria in humans, including vector bacteria and opened the field of large deoxyribonucleic acid (dna ) viruses. also, the laboratory of emerging viruses discovered many ribonucleic acid (rna) viruses transmitted by arthropods. based on this collection of new pathogens described in poc laboratory, this study proposes to expand the etiological diagnosis strategy of diarrhoea after poc tests.


Eligibility criteria:
inclusion criteria: * patient admitted at hospital for diarrhoea requiring, for the emergency physician, a microbiological examination with a "poc diarrhoea kit." * patient who has freely signed the informed written consent * patient affiliated to a social security scheme exclusion criteria: * pregnant woman, parturient or nursing * adult major under guardianship * patient deprived of liberty under court order * patient refusing or unable to sign the informed consent form.